

VACCINE
WORLD ASIA CONGRESS 2026
South East Asia

SEA Vaccine Landscape

Approved Vaccines, Clinical Development Pipeline & Market Outlook

Presented by

**Vaccine World Asia Congress 2026 –
South East Asia**

 Sheraton Grand Jakarta
Gandaria City Hotel

 14–15 October 2026



COMPREHENSIVE
VACCINE LANDSCAPE



CLINICAL PIPELINE
ANALYSIS



MARKET OUTLOOK &
STRATEGIC INSIGHTS



SHAPING THE FUTURE
OF IMMUNIZATION

REPORT OVERVIEW

The Southeast Asia Vaccine Landscape

One of the world's most dynamic vaccine markets — powered by a high burden of infectious disease, expanding government immunisation programmes, and fast-growing local manufacturing.

Southeast Asia continues to be one of the world's most important vaccine markets, driven by a high burden of infectious diseases, growing government immunisation programmes, expanding local manufacturing capabilities, and rising investment in next-generation vaccine technologies.

Countries such as **Singapore, Indonesia, Thailand, Vietnam, and Malaysia** are strengthening their vaccine ecosystems through partnerships with global pharmaceutical companies, regional biotech firms, academic institutions, and public-health agencies. This report provides a comprehensive overview of vaccine programmes relevant to the region — covering approved products, late-stage clinical candidates, early-stage innovations, and the organisations shaping the future of vaccine development.




The landscape tracks vaccines targeting major public-health priorities including **dengue, COVID-19, influenza, RSV, tuberculosis, EV71, chikungunya, mpox**, and emerging pandemic threats.



How to read this report. Vaccines are grouped by development status — from products already on the market through to candidates in Phase I–III clinical trials. Colour-coded badges indicate each programme's stage, while platform and disease-area tags highlight the technologies and public-health targets driving innovation across Southeast Asia.

01 Approved & Commercialised Vaccines

Products with regulatory approval or active commercial distribution across ASEAN and global markets, spanning dengue, COVID-19, RSV, and core national immunisation programmes.













ORGANISATION	COUNTRY	VACCINE CANDIDATE(S)	DISEASE AREA	PLATFORM	STATUS
	Japan / ASEAN	Qdenga	Dengue	Live Attenuated	Approved
	Global / ASEAN	Dengvaxia	Dengue	Live Attenuated	Approved
	Indonesia	IndoVac	COVID-19	Recombinant Protein	Approved
	Taiwan / ASEAN	ENVACGEN EV71	EV71 (HFMD)	Inactivated	Approved
	South Korea	SKYCovione	COVID-19	Protein-Based	Approved
	Global	Nuvaxovid	COVID-19	Recombinant Protein	Approved
	Global	Arexvy	RSV	Recombinant Adjuvanted	Approved
	Global	Abrysvo	RSV	Bivalent Vaccine	Approved
	Global	Shingrix	Herpes Zoster	Recombinant	Approved
	Global	Prevenar 20	Pneumococcal Disease	Conjugate Vaccine	Approved
	Indonesia	OPV · BCG · Measles-Rubella	Polio · TB · Measles/Rubella	Live Attenuated	Commercialised
	Vietnam	Seasonal Influenza Vaccine	Influenza	Inactivated	Commercialised
	Vietnam	Japanese Encephalitis · Rabies	JE · Rabies	Inactivated · Cell Culture	Commercialised
	Vietnam	Measles · Rubella Vaccine	Measles · Rubella	Live Attenuated	Commercialised
	Vietnam	Oral Cholera Vaccine	Cholera	Oral Inactivated	Commercialised

Approved Regulatory approval secured

Commercialised In active national distribution

02 Clinical Development Pipeline • Phase I–III

Next-generation and late-stage candidates advancing through clinical trials — including mRNA, self-amplifying RNA, viral-vector, and combination platforms targeting emerging and re-emerging threats.

ORGANISATION	COUNTRY	VACCINE CANDIDATE(S)	DISEASE AREA	PLATFORM	STAGE
	Global	Pan-Coronavirus Vaccines	Coronavirus	Next-Gen Platforms	Phase I
	Global	Universal Influenza Programs	Influenza	Multiple Platforms	Phase I/II
	United Kingdom	ChAdOx1 Nipah Vaccine	Nipah Virus	Viral Vector	Phase I/II
	Thailand	ChulaCov19	COVID-19	mRNA	Phase II
	Singapore	ARCT-154 Expansion	COVID-19	Self-Amplifying RNA	Phase II
	Vietnam	Nanocovax	COVID-19	Recombinant Protein	Phase II
	United States	Epstein-Barr Virus Vaccine	EBV	mRNA	Phase II
	United States	V181	Dengue	Live Attenuated	Phase III
	United Kingdom	M72/AS01E	Tuberculosis	Protein-Adjuvant	Phase III
	South Korea	BARYCELA	Varicella	Live Attenuated	Phase III
	France	Hexavalent Pediatric Vaccine	Pediatric Diseases	Combination Vaccine	Phase III
	United States	mRNA-1083 · CMV · RSV	COVID+Flu · CMV · RSV	Combination mRNA	Phase III

Phase I

Phase I/II

Phase II

Phase III

Late-stage, nearing approval

As Southeast Asia strengthens its role in vaccine innovation, clinical development, and manufacturing, collaboration across **industry, academia, regulators, and public-health stakeholders** remains critical to advancing vaccine access and innovation throughout the region.

To gain further insights into these developments, join us at Vaccine World South East Asia (VWSEA) 2026, where leading experts and decision-makers from across the vaccine ecosystem will share their perspectives on the trends, technologies, and strategies shaping the future of vaccination in the region.

Meet some of the industry leaders and experts speaking at VWSEA 2026

CONFIRMED SPEAKERS



Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer
Pharmaniaga Berhad
 Malaysia



Dr. Mohd Azlan bin Zaharudin
Director
Malaysian Vaccine Project Office (MVPO), MOSTI
 Malaysia



Dr. Uma Nath Tripathi
Associate General Manager
Kashiv Biosciences LLC
 India



Dr. Heba Wali
Vice CEO
VBC Vaccines and Biotechnology City
 Egypt



Zainab Sadat
General Manager, Vaccines, Southeast Asia & India MCO
Sanofi
 Singapore



Meenu Batolar
Global Regulatory Affairs Asia Pacific Lead
CEPI
 Singapore



Dr. Sushant Sahastrabudde
Deputy Director General
International Vaccine Institute (IVI)
 South Korea



M. Indra Lamora
Director — Anti Infectious Department
Etana Technologies
 Indonesia



Dr. Vinod Kumar Bura
Coordinator, IVD Unit
WHO SEARO
 India



Indriana Permatasari
Project Manager
International Vaccine Institute (IVI)
 Indonesia



Dr. Soleh Ayubi
Chief of Country Representative
PATH
 Indonesia



Dr. Mandeep Singh Dhingra
Director and Head, R&D Programs
CEPI
 USA



Dr. Jetsumon Sattabongkot Prachumsri
Director
Mahidol Vivax Research Unit, Mahidol University
 Thailand



Dr. Deepak Mukherjee
Country Medical Director
Roche
 Indonesia



Dr. Karan Thakkar
Vaccines Medical Director
Pfizer
 Singapore